Company ProfilePremium

Aarti Drugs Limited

Company Profile Analysis

Tickers: AARTIDRUGS.NS, 524348.BO

ESOMAR 23 Corporate BadgeISO Certifications Badge
Aarti Drugs Limited - Company showcase

Year Founded & Workforce

1984

Aarti Drugs Limited logo

Aarti Drugs Limited Employee Contacts

4 verified contactsNames, job titles, seniority and locations

View Employee Contacts

Aarti Drugs Limited Overview

Aarti Drugs Limited is a mid-sized, backward-integrated Indian bulk-drug manufacturer whose core franchise is high-volume, mature generic Active Pharmaceutical Ingredients (APIs) across anti-infective, anti-protozoal, anti-diabetic, anti-inflammatory and anti-fungal therapies. The company claims global leadership in Nimesulide, Ketoconazole, Metronidazole Benzoate, Tinidazole and fluoroquinolones, and is a leading Metformin producer. APIs contributed 77% of FY2026 consolidated revenue of ₹2,568 crore, with formulations (largely export-led, via the company and its wholly owned subsidiary Pinnacle Life Science), specialty chemicals and intermediates making up the balance. Having completed a roughly ₹600 crore investment cycle — notably a methylamines backward-integration plant at Sayakha, Gujarat and a salicylic-acid plant at Tarapur — the company is now in a ramp-up phase aimed at restoring EBITDA margins to 13.5–14%, shifting mix toward regulated markets (73% of the relevant mix in FY2026) and reducing dependence on Chinese key starting materials.


Company's own description

In its FY2026–FY2027 investor releases, the company describes itself as a diversified and fully integrated pharmaceutical company with interests in Active Pharmaceutical Ingredients, Formulations, Specialty Chemicals and Intermediates, which manufactures APIs, pharma intermediates and specialty chemicals and produces formulations through its wholly owned subsidiary Pinnacle Life Science Private Limited. Its investor presentations position it as a leading API producer with a portfolio of 50+ molecules spanning antibiotics, anti-protozoals, anti-inflammatories, anti-diabetics and anti-fungals, and state that it exports APIs and specialty chemicals to more than 100 countries.

Independent characterisation

Aarti Drugs is fundamentally a volume-driven, cost-competitive commodity-generic API manufacturer that has spent the last five years attempting to migrate up three ladders simultaneously:

  1. Up the regulatory ladder — from semi-regulated/domestic API supply toward US/EU-registered APIs and export formulations (USFDA "VAI" status for its Tarapur E-22 API site in December 2024; regulated-market contribution rising from 66% in FY2025 to 73% in FY2026).

  2. Down the value chain (backward integration) — internalising key starting materials and intermediates (methylamines at Sayakha for Metformin; salicylic acid at Tarapur; captive PTSCL and other chlorosulfonation chemistry), primarily to de-risk Chinese input dependence and protect margins.

  3. Into adjacent businesses — formulations (including a USFDA-approved oncology formulation capability, per the Q1 FY2027 investor presentation) and specialty chemicals (benzene sulphonyl chloride, methyl nicotinate, salicylic acid and derivatives).

Business and revenue model

DimensionCharacterisation
Revenue model~100% product sales (bulk API, intermediates, specialty chemicals, finished formulations). No material service, subscription or licensing revenue disclosed.
PricingLargely spot/contract pricing for commodity APIs; realisations highly sensitive to Chinese supply and raw-material (crude-linked) costs. Management repeatedly cites "negative rate variance" in FY2024–FY2025 and "pricing pressure in select API segments" in FY2026.
Value-chain positionMid-stream: converts basic/petrochemical feedstocks and intermediates into APIs; increasingly upstream (KSMs) and selectively downstream (formulations).
Customer typesDomestic and international formulation companies (generic manufacturers), specialty-chemical buyers, government/tender buyers for formulations (e.g., Chile via Pinnacle Chile SpA), and distributors. FY2025 BRSR states the company serves pharmaceutical formulation companies and specialty-chemical customers.
End-marketsHuman generic pharmaceuticals (anti-infectives, anti-diabetics, analgesics/anti-inflammatories, anti-fungals, CNS e.g. Zolpidem, women's health e.g. Raloxifene), nutrition (Niacin), and industrial/specialty chemical users.
Reportable segment (Ind AS 108)The company reports a single operating segment ("Pharmaceuticals"), with geographic segmentation of India vs Out of India (per MarketScreener summary of filings). Business-vertical revenue (API / Formulation / Specialty Chemicals / Intermediates & Others) is disclosed voluntarily in investor releases and is used throughout this dossier.

Therapeutic mix within API (Q3 FY2026, company investor release)

Therapeutic categoryShare of API sales (%)
Antibiotics (incl. fluoroquinolones)35.1
Anti-protozoal19.8
Anti-diabetic16.6
Anti-inflammatory12.9
Anti-fungal12.2
Others3.4 (derived)

In Q1 FY2027 the antibiotic share was 35.0% (company investor release, 1 August 2026), indicating a stable mix.

Strategy

Stated strategic themes (company releases, FY2026–FY2027)

Backward integration and input security: Investments in methylamines (Sayakha) and salicylic acid (Tarapur) to strengthen margin performance and reduce exposure to raw-material volatility.

Regulated-market pivot: Prioritising US and EU regulatory filings and approvals, which management expects to open margin-expansion opportunities.

Export formulations as a value driver: Management expects the formulations business to become a primary value driver, citing strong export traction.

Downstream specialty chemicals: A salicylates line downstream of salicylic acid is being implemented, which management believes can transform the specialty-chemicals vertical.

  • Operational efficiency and capacity enhancement, alongside disciplined procurement (Q1 FY2027 CFO commentary).

Governance continuity: The 2026 leadership transition was explicitly framed as not altering long-term strategic direction.

Initiative register (last 24 months)

InitiativeDateDetailStatus
Sayakha greenfield (methylamines)Trial Jul 2025; commercial 4 Sep 2025Target >800 t/month, installed ~1,600 t/month by end FY2026 (stated Jul 2025); ~1,000 t/month achieved Mar 2026; 65% utilisation Q1 FY2027Ramping; brief GPCB closure Jul 2026, revoked
Tarapur salicylic-acid greenfieldExpected contribution from Q3 FY2026>300 t/month achieved early 2026Ramping
Salicylates downstream lineAnnounced Feb 2026Under implementationIn progress
Tarapur API expansionJul 2025 commentaryMore production blocks planned at USFDA-approved site; new regulated-customer audits triggeredPlanned
Brownfield programmeMay 2026₹300–400 crore over coming yearsPlanned
Chile market entryNov 2024 / Mar 2026Pinnacle Chile SpA; Tripharma Chile SpAOperational/early
Pinnacle recapitalisationMar 2026₹10 crore equity infusionCompleted
Shareholder returnsAug–Sep 2024; Feb 2026₹59.85 crore buyback; doubled interim dividend to ₹2Completed
Investor engagementMay–Jun 2026Analyst meets with 360 ONE Capital (27 May) and Choice Institutional Equities (10 Jun)Completed

ESG/sustainability commitments

BRSR filed for FY2025 and FY2026. Specific quantified emissions targets were not publicly disclosed in retrieved sources. Post-GPCB, the company stated it is implementing corrective and preventive measures to avoid future lapses.

Medium-term guidance

MetricGuidanceSource
FY2027 EBITDA margin13.5%–14% (despite higher crude prices and West Asia uncertainty)Q4 FY2026 call (FilingReader, 23 May 2026)
Brownfield capex₹300–400 crore over coming yearsQ4 FY2026 call
Medium-term capex (rating-agency view)₹150–200 crore p.a.CRISIL, Jan 2026
Revenue growth target——

Products & Services

The company does not publish a priced catalogue; the following is assembled from regulatory disclosures, investor presentations and company statements. Launch years and pricing are not publicly disclosed unless noted.

APIs (50+ molecules)

ProductTherapyNotes / capabilitiesSource
Metformin HClAnti-diabeticAmong the world's leading producers (company profile); Sayakha methylamines plant built to backward-integrate MetforminGroww company profile; Sahi summary of GPCB filing
NimesulideAnti-inflammatoryCompany claims largest global producerAGM 2026 presentation
KetoconazoleAnti-fungalCompany claims largest global producerAGM 2026 presentation
Metronidazole / Metronidazole BenzoateAnti-protozoalCompany claims largest global producer of the benzoate; largest Metronidazole producer in IndiaAGM 2026 presentation; Groww profile
TinidazoleAnti-protozoalCompany claims largest global producerAGM 2026 presentation
Fluoroquinolones (incl. Ciprofloxacin HCl; others such as Ofloxacin/Norfloxacin — individual molecules not re-verified)AntibioticCompany claims global leadership in fluoroquinolones; Ciprofloxacin HCl cleared for US supply post-EIRAGM 2026 presentation; Dec 2024 EIR disclosure
Zolpidem TartrateCNS (hypnotic)US-market supply enabled after Dec 2024 EIRCompany disclosure
Raloxifene HClWomen's health (osteoporosis)US-market supply enabledCompany disclosure
CelecoxibAnti-inflammatory (COX-2)US-market supply enabledCompany disclosure
NiacinVitamin / lipidUS-market supply enabledCompany disclosure

Formulations

OfferingDescriptionSource
Export formulations65% of FY2026 standalone formulation sales were exports (74% in Q1 FY2027); strong growth into regulated marketsFY2026 and Q1 FY2027 releases
Oncology formulationsUSFDA-approved oncology formulation capabilityQ1 FY2027 investor presentation
Pinnacle Life ScienceWholly owned formulation subsidiary (domestic and export); recapitalised with ₹10 crore in March 2026Company filings
Chile tender businessPinnacle Chile SpA / Tripharma Chile SpA for Chilean public tenders and private marketFY2025 Directors' Report; Mar 2026 filing

Specialty chemicals & intermediates

ProductDescriptionSource
Benzene sulphonyl chlorideSpecialty chemical (sulphonation/chlorosulphonation chemistry)MarketScreener company description
Methyl nicotinateSpecialty chemicalMarketScreener company description
PTSCL (para-toluene sulphonyl chloride)Captive and merchant sale; chlorosulfonation at T-150, Tarapur (paused Sept 2025 after HCl leak)Company filing, Sept 2025
Methylamines (Sayakha, Gujarat)Backward integration for Metformin; commercial production 4 Sep 2025; ~1,000 t/month by Mar 2026; 65% utilisation in Q1 FY2027Company releases; Quartr Q1 FY2027 summary
Salicylic acid (Tarapur greenfield)Scaled to >300 t/month by early 2026; downstream salicylates line under implementationQ3 FY2026 commentary
NCB-based specialty chemicalsCompany noted for strong position in nitrochlorobenzene-based chemistry (aggregator characterisation)AlphaStreet profile

Financial Narrative

Income statement (consolidated, ₹ crore)

Sources: Revenue, gross profit and interest — StockAnalysis (converted from INR millions); EBITDA, PBT, PAT — Anand Rathi summary of reported results; FY2026 cross-checked to company release (revenue ₹2,567.7 crore total revenue; EBITDA ₹311.6 crore; PBT ₹210.9 crore; PAT ₹194.9 crore). Company-defined FY2026 gross profit is ₹949.0 crore (FY2025: ₹861.3 crore), which differs from the aggregator definition shown.

(derived from table above; company reports FY2026 EBITDA margin 12.1% and PAT margin 7.6%, FY2025 12.6% and 7.0%)

Sources: Company FY2026 release (EPS); FY2025 Directors' Report (₹1 interim); Feb 2026 filing (₹2 interim). Basic and diluted EPS are identical (no dilutive instruments disclosed). Dividends of ~₹9.2 crore (≈₹1/share) are referenced by ICRA for the FY2024 period.

Revenue CAGR FY2022–FY2026: 0.8% (derived). PAT CAGR FY2022–FY2026: −1.3% (derived). Screener's machine summary similarly flags weak five-year sales growth.

Commentary. The five-year picture is one of stagnation followed by a tentative recovery. Revenue peaked in FY2023 at ₹2,716 crore on the back of ~10% API price increases, then fell 6.9% in FY2024 and 5.6% in FY2025 as post-COVID industry overcapacity and Chinese price competition drove "negative rate variance" — the company's own Q1 FY2027 presentation attributes post-COVID revenue weakness to industry-wide oversupply and sharp API price erosion. Gross margin (aggregator basis) actually expanded from ~30% to ~37% over the period as input costs fell faster than realisations, but this was absorbed by rising operating costs (other operating expenses rose from ₹364 crore to ₹506 crore, per StockAnalysis) and new-plant start-up costs, keeping EBITDA margin in an 11–14% band. FY2026 PAT growth of 16% outpaced EBITDA growth of 3% largely because of a low effective tax rate (PAT ₹194.9 crore on PBT ₹210.9 crore), including a ~₹15 crore principal tax refund booked in Q1 FY2026 — so FY2026's earnings quality is somewhat flattered.

Quarterly trajectory (consolidated, ₹ crore)

Sources: Company quarterly releases. Q2 FY2026 EBITDA and PAT (derived from 9M FY2026 EBITDA ₹215.0 crore and PAT ₹139.7 crore). Q1/Q2 FY2026 PBT (derived from FY2026 PBT and Q3/Q4 actuals and Q1 FY2027's +35% YoY PBT growth implying Q1 FY2026 PBT of ~₹51.1 crore). Q1 FY2027 EBITDA/PBT/PAT include ~₹2 crore CWIP write-off; Q1 FY2026 PAT includes ~₹15 crore tax refund.

Commentary. The Q3 FY2026 trough (9.3% EBITDA margin) coincided with Sayakha's initial scale-up costs; the subsequent two quarters at 13.4–13.8% suggest the company is approaching management's FY2027 margin target of 13.5–14%. On a like-for-like basis (excluding the Q1 FY2026 tax refund), Q1 FY2027 PAT rose meaningfully rather than falling 7%.

Balance sheet (selected, ₹ crore)

Sources: ICRA rationales (Mar 2022 and Mar 2025 balance-sheet dates). CRISIL cites ₹612 crore at 31 Mar 2025 — minor discrepancy with ICRA's ₹615.1 crore, both noted.

Additional verified balance-sheet data points (not available for all five years):

Goodwill & intangibles and a full working-capital breakdown are not publicly disclosed in retrieved sources (the company is asset-heavy with negligible acquired goodwill; no material acquisitions identified). Net debt at 30 Sep 2025 was approximately ₹561–564 crore (derived).

Commentary. Leverage rose through the capex cycle (cumulative ~₹600 crore per ICRA) — total debt/OPBDITA drifted from 1.6x to 2.1–2.2x — but working-capital release brought debt down by ~₹40 crore in H1 FY2026. Liquidity is managed through large working-capital lines rather than cash balances (cash of under ₹10 crore against ₹1,085 crore of short-term limits), a typical Indian mid-cap API structure. CRISIL expects ~₹220 crore of annual cash accrual against term-debt obligations of ₹40–70 crore and capex of ₹150–200 crore per annum — i.e., limited free cash after capex and buybacks.

Cash flow

Commentary. Capital allocation has been notably shareholder-friendly for a company of this size, with four tender buybacks in seven years, while dividends have remained token (Screener notes a ~5% payout over three years). This pattern — buybacks favoured over dividends — reflects Indian tax considerations and promoter participation choices.

Ratios

Commentary. Returns have compressed from the COVID-era peak (FY2021 PAT ₹280 crore) to low-teens ROE, with ROCE of 11.5% in FY2026 sitting close to a reasonable cost of capital — the capex cycle has diluted returns pending ramp-up. Interest coverage halved between FY2022 and FY2023 as debt and rates rose, but has been stable since.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityRelationshipFunctionSource

Aarti Drugs Limited

Listed parent

APIs, intermediates, specialty chemicals, standalone formulations; contributed 89% of consolidated revenue in Q1 FY2027

Q1 FY2027 release

Pinnacle Life Science Private Limited

100% subsidiary

Finished-dosage formulations

FY2025 BRSR; company releases

Aarti Speciality Chemicals Limited

100% subsidiary

Specialty chemicals vehicle

FY2025 BRSR

Pinnacle Chile SpA

Subsidiary (incorporated 27 Nov 2024)

Marketing formulations; Chilean tenders and private market

FY2025 Directors' Report

Tripharma Chile SpA

Step-down subsidiary (incorporated 2 Mar 2026)

Chilean market expansion (precise scope not disclosed)

Company filing summary

Revenue by Segment

Segment (INR Cr, consolidated)FY2025FY2026

API

1,938.41,979.4

Formulations

248.9331.2

Specialty Chemicals

130.0178.3

Intermediates & Others

69.476.4

Total revenue from operations

2,386.72,565.3

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Segment share of revenue (%)

Segment share of revenue (%)FY2025FY2026

API

81.277.2

Formulations

10.412.9

Specialty Chemicals

5.47.0

Intermediates & Others

2.93.0

Segment YoY growth (%)

Segment YoY growth (%)FY2026

API

2

Formulations

33

Specialty Chemicals

37

Intermediates & Others

10

Revenue by Segment (Quarterly)

Segment (INR Cr)Q4FY2025Q3FY2026Q4FY2026Q1FY2026Q1FY2027

API

553.1454.3551.0458.2510.4

Formulations

64.876.492.080.386.2

Specialty Chemicals

39.051.156.833.182.6

Income Statement

Metric (INR Cr, consolidated)FY2022FY2023FY2024FY2025FY2026

Revenue from operations

2,488.62,716.12,528.62,387.02,565.3

Gross profit (aggregator definition)

786.5805.8831.6825.6946.6

EBITDA (operating profit)

340.8307.8320.5303.4311.6

Interest expense

20.733.333.535.933.7

Profit before tax

270.0224.2235.5211.8210.9

Net profit (PAT)

205.0166.4171.6168.1194.9

Margin (%)

Margin (%)FY2022FY2023FY2024FY2025FY2026

Gross margin (aggregator definition)

31.629.732.934.636.9

EBITDA margin

13.711.312.712.712.1

PBT margin

10.88.39.38.98.2

Net margin

8.26.16.87.07.6

Per-share data (INR)

Per-share data (INR)FY2025FY2026

EPS basic/diluted (consolidated)

18.4421.36

Dividend per share

12

Income Statement and Margin Analysis (%)

Metric (INR Cr)Q1FY2026Q2FY2026Q3FY2026Q4FY2026Q1FY2027

Total revenue

590.8652.9602.9721.1703.6

EBITDA

74.484.356.396.696.9

EBITDA margin (%)

12.612.99.313.413.8

PBT

51.160.429.070.469.2

PAT

54.045.240.555.350.1

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Financials

Metric (INR Cr)FY2022FY2025

Total debt (consolidated)

542.8615.1

Data Point Details

Data pointValueDateSource

Total debt

₹589.1 crore

30 Sep 2023

ICRA

Total debt

₹596.5 crore

31 Dec 2023

ICRA

Total debt

₹590.1 crore

30 Sep 2024

ICRA

Total debt

₹571 crore (CRISIL) / ₹573.5 crore (ICRA)

30 Sep 2025

CRISIL Jan 2026; ICRA Mar 2026

Cash & equivalents (unencumbered, incl. investments)

₹9.57 crore

30 Sep 2025

CRISIL Jan 2026

Gearing (debt/equity)

0.39x

30 Sep 2025

CRISIL Jan 2026

Total debt / OPBDITA

1.6x (Mar 2022); 1.8x (Mar 2023); 2.1x (Mar 2025); 2.2x (Sep 2024)

various

ICRA

Net worth

₹1,549 crore

31 Mar 2026

AGM 2026 presentation

Book value per share

~₹154–161

2026

Screener / Groww (data-date dependent)

Rated bank facilities

₹1,452.80 crore (ICRA); ₹1,768 crore (CRISIL)

Mar 2026 / Jan 2026

Rating rationales

Short-term fund/non-fund-based limits

₹1,085 crore

Mar 2026

ICRA

Term loans rated

₹253.13 crore (+₹49.67 crore proposed)

Mar 2026

ICRA

Regulated-market contribution

66% → 73%

FY2025 → FY2026

FY2026 results release

Formulation exports share (standalone)

65%

FY2026

FY2026 release

Formulation exports share

69%

Q4 FY2026

FY2026 release

Formulation exports share

74%

Q1 FY2027

Q1 FY2027 release

Formulation exports share

53%

Q2 FY2025

Q2 FY2025 earnings call

Formulation exports share (9M)

64%

9M FY2026

Q3 FY2026 release

Domestic revenue growth

+25% YoY

Q1 FY2027

Q1 FY2027 release

Export revenue growth

+12% YoY

Q1 FY2027

Q1 FY2027 release

Countries served

100+

2026

AGM 2026 presentation

Formulation export share (%)

Q2FY2025

Q4FY2026

Q1FY2027

Exports as % of formulation revenue

536974

Financial Analysis

MetricDisclosure status

Operating cash flow (5 years)

Not publicly disclosed in retrieved sources

Capex

~₹220–230 crore expected FY2024 and FY2025 (ICRA 2024); ~₹150 crore expected FY2026 (ICRA 2026); ₹150–200 crore p.a. medium term (CRISIL); ₹300–400 crore brownfield programme announced May 2026

Dividends paid

~₹9.1–9.2 crore p.a. at ₹1/share (FY2024–FY2025); ~₹18.3 crore at ₹2/share (FY2026, derived)

Buybacks

FY2018 ~₹24.1 crore; FY2021 up to ₹60 crore; FY2023–24 ~₹60 crore (₹73.2 crore incl. tax); FY2025 ₹59.85 crore

Financial Analysis — ROCE

RatioValuePeriodSource

ROCE

11.5%

FY2026

AGM 2026 presentation

ROE

~12.7–13.6%

TTM 2026

Screener; Groww

Debt/equity

0.39x

Sep 2025 / 2026

CRISIL; Groww

Total debt / OPBDITA

2.1x

Mar 2025

ICRA

Interest coverage (EBITDA/interest)

9.2x

FY2026 (derived)

—

Interest coverage (EBITDA/interest)

16.5x

FY2022 (derived)

—

ROA, ROIC, current ratio, asset turnover, cash conversion cycle

Not publicly disclosed in retrieved sources

——

Ratio

FY2022

FY2023

FY2024

EBITDA / interest (x, derived)

16.59.29.6

Valuation Snapshot

MetricValueDateSource

Share price (NSE)

₹415

5 Oct 2026

IIFL

Market capitalisation

₹3,787.7 crore

5 Oct 2026

IIFL

52-week range

₹318.95 – ₹534

As of 5 Oct 2026

IIFL

P/E

22.3x (reported basis)

5 Oct 2026

IIFL

P/E on TTM consolidated PAT

~19.8x (derived; TTM PAT ₹191.0 crore)

Oct 2026

—

P/B

2.74x

5 Oct 2026

IIFL

EV (approx.)

~₹4,380 crore (derived: market cap + ~₹600 crore debt − ~₹10 crore cash)

Oct 2026

—

EV/EBITDA (FY2026)

~14.1x (derived)

——

EV/EBITDA (TTM, EBITDA ₹334.1 crore)

~13.1x (derived)

——

EV/Sales (TTM revenue ₹2,677.6 crore)

~1.6x (derived)

——

1-year share-price return

~−8%

Oct 2026

IIFL

Share price checkpoints (INR)

Jun2026

Jul2026

Aug2026

Closing price

370424418

Dividend per share (INR)

Dividend per share (INR)FY2025FY2026

Interim dividend

12

Capital Programmes

ProgrammePrice (₹/share)SizeSharesSource

Jan 2018

875

~₹24.1 crore

~0.27 million

Business Standard

Mar 2021

1,000

Up to ₹60 crore

Up to 0.6 million

Business Standard

FY2023–FY2024

—

~₹60 crore (₹73.2 crore incl. tax)

—

ICRA

Aug–Sep 2024

900

₹59.85 crore

0.665 million (0.72%)

BSE filing; NSE circular

Credit Ratings

AgencyLong-termShort-termOutlookAmount ratedDate

ICRA

[ICRA]AA-

[ICRA]A1+

Stable

₹1,452.80 crore

24 Mar 2026

CRISIL

Crisil AA-

Crisil A1+

Stable

₹1,768 crore

28 Jan 2026

Moody's / S&P / Fitch

Not rated

————

Analyst Conclusions

Management guidance

  • FY2027 EBITDA margin of 13.5%–14% (Q1 FY2027 delivered 13.8%).

  • Continued ramp-up of Sayakha (65% utilisation in Q1 FY2027) and salicylic acid, with salicylates downstream line under implementation.

  • ₹300–400 crore brownfield capex over coming years; priority on US/EU filings.

  • Encouraging demand outlook across APIs, specialty chemicals and formulations (Q1 FY2027 CFO commentary).

Consensus expectations

Not publicly available (no verified consensus).

Bull case

  1. Margin inflection is underway: EBITDA margin moved from 9.3% (Q3 FY2026) to 13.8% (Q1 FY2027); sustaining 14% on ~₹2,800 crore revenue would imply EBITDA of ~₹390 crore vs ₹311.6 crore in FY2026 (analyst illustration, not guidance).

  2. Diversified growth engines: Specialty chemicals (+150% YoY in Q1 FY2027) and export formulations (74% export share) are compounding off small bases and carry better pricing power than commodity APIs.

  3. Overhangs removed and balance sheet sound: Supreme Court dismissal of the ₹251 crore GST claim, GPCB revocation within two weeks, and AA- ratings with 0.39x gearing reduce tail risks at an undemanding ~13x TTM EV/EBITDA.

Bear case

  1. Structural commodity exposure: API (77% of revenue) grew only 2% in FY2026; any renewed Chinese price aggression can erase backward-integration gains, as FY2024–FY2025 demonstrated.

  2. EHS pattern risk: Three pollution-board actions in two years; a prolonged closure at Sayakha or Tarapur would hit both cost structure and the regulated-customer narrative.

  3. Capital intensity vs returns: ROCE of 11.5% after ~₹600 crore of capex, with a further ₹300–400 crore planned, risks value-neutral growth if utilisation and pricing disappoint; thin cash and buyback-heavy allocation leave limited buffer.

Catalysts and monitorables (next 12 months)

Catalyst / monitorableTimingWhat to watch
Q2 FY2027 resultsExpected late Oct–mid Nov 2026 (date unconfirmed)Margin sustainability ≥13.5%; Sayakha utilisation post-GPCB
New leadership's first strategic communicationH2 FY2027Capital-allocation framework; CFO appointment
USFDA/EU inspections and approvalsOngoingAny Form 483s; new DMF/CEP approvals
Salicylates line commissioningFY2027 (timing not disclosed)Revenue contribution
Brownfield capex executionFY2027–FY2028Debt trajectory vs ~₹220 crore accrual
EHS complianceOngoingAny further MPCB/GPCB actions; PTSCL resumption
API price environmentOngoingChina export pricing for metformin, metronidazole, fluoroquinolones
Rating surveillanceICRA due by Mar 2027Outlook stability

Analyst verdict

Aarti Drugs enters FY2027 in a better position than at any point since the post-COVID API downcycle began. The heavy lifting of its investment cycle is done: the Sayakha methylamines plant is producing at scale, the Tarapur salicylic-acid plant is ramping, the Tarapur API site holds USFDA VAI status, and two of the three most visible overhangs of the past year — the ₹251 crore GST dispute and the Sayakha closure order — have been resolved in its favour within weeks of each other. Q1 FY2027's 19% revenue growth and 13.8% EBITDA margin suggest that management's 13.5–14% FY2027 margin target is achievable, and the stock, at roughly 20x trailing earnings and 13x EV/EBITDA, does not price in a sustained recovery.

Yet the investment case remains that of a cyclical, commodity-API producer attempting a structural re-rating, and the evidence for the structural part is still early. API revenue — over three-quarters of the business — grew just 2% in FY2026; return on capital (11.5%) has not yet responded to the ₹600 crore deployed; and the EHS record, with three pollution-board interventions in two years, is inconsistent with a company courting Western regulated customers. The October 2026 leadership transition consolidates authority under Rashesh Gogri, who brings group-wide chemistry depth but also carries simultaneous top roles at two other listed Aarti companies.

Our synthesis: the near-term earnings trajectory is favourable and downside appears cushioned by valuation, credit quality and resolved legal overhangs, but a durable re-rating requires (i) two to three more quarters of 13.5%+ margins without one-offs, (ii) visible growth in API volumes into regulated markets, and (iii) an incident-free EHS record. Absent those, Aarti Drugs is best viewed as a well-managed cyclical recovery play rather than a compounding franchise.


SOURCE LIST (primary and secondary documents consulted)

  • Company investor releases and presentations: Q1 FY2026 (Jul 2025), Q3 FY2026 (Feb 2026), Q4/FY2026 (May 2026), Q1 FY2027 (1 Aug 2026) — NSE/BSE archives

  • Company Regulation 30 filings: GST litigation (6 Oct 2025; 16 Mar 2026; 10 Aug 2026); GPCB closure and revocation (18 Jul 2026; 1 Aug 2026); MPCB orders (17 Jul 2024; 7 Aug 2024; Sep 2025); leadership transition (31 Jul 2026); credit rating (24 Mar 2026); buyback (Aug 2024)

  • FY2025 Directors' Report (via IIFL); FY2025 BRSR (NSE)

  • ICRA rating rationales (2024, Mar 2026); CRISIL rating rationale (28 Jan 2026)

  • NSE circular CMTR63946 (Sep 2024)

  • Aggregators: StockAnalysis, Anand Rathi, Screener, IIFL, Groww, Choice India, Finology Ticker, share.market, 5paisa, MarketScreener, Quartr

  • News: Indian Pharma Post, Business Standard, FilingReader, ScanX, Medical Dialogues, Sahi, Multibagg, Investywise

  • Peer data: IOL Chemicals & Pharmaceuticals Q4 FY2026 and Q1 FY2027 releases; Aarti Pharmalabs results (Anand Rathi)

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameTitleTenure / backgroundSource

Rashesh C. Gogri

Chairman & Managing Director

MD since Sep 2014 (previously Whole-time Director); 27+ years in production, marketing and project implementation in chemicals/pharma; also Vice Chairman & MD of Aarti Industries Ltd and Chairman of Aarti Pharmalabs Ltd. Promoter. Chairman from 1 Oct 2026

Company press release, 31 Jul 2026

Adhish P. Patil (DIN 02629496)

Managing Director (5-year term from 1 Oct 2026, subject to shareholder approval at AGM)

Previously CFO & COO. Sources conflict on tenure: CNBC-TV18 cites 25+ years of association; the company press release references "over a decade" — discrepancy noted

Company filing; CNBC-TV18 via AskFuzz

Harshit M. Savla

Joint Managing Director (re-appointed)

Promoter-group executive

CNBC-TV18 summary of board outcome

Harit P. Shah

Whole-time Director (re-appointed)

Participated in earnings calls (Q2 FY2025)

Board outcome; Q2 FY2025 call

Prakash M. Patil (DIN 00005618)

Former Chairman, MD & CEO (retired 30 Sep 2026; advisory role continues)

Associated since inception; Chairman since 2014

Company press release

Uday M. Patil

Former Whole-time Director

Ceased; did not seek re-appointment

Board outcome, 31 Jul 2026

CFO (successor to Adhish Patil)

Not publicly disclosed in retrieved sources

——

Governance Overview

FeatureDetailSource

Chair/CEO separation

No — Chairman has been an Executive Director (FY2025 Directors' Report); from 1 Oct 2026 the Chairman is also MD (executive chair)

FY2025 Directors' Report; Jul 2026 filing

Independent directors (named in retrieved filings)

Salvi (added to Risk Management Committee, May 2026)

FY2025 Directors' Report; board outcomes

Committees

Audit; Nomination & Remuneration (recommended the 2026 transition); Risk Management (re-constituted May 2026 and Oct 2026); others re-constituted effective 1 Oct 2026

Company filings

Board-level independence %

Not publicly disclosed in retrieved sources (SEBI LODR requires at least 50% independent directors where the Chairman is executive)

—

Board & Management Changes

DateChangeContext

31 Jul 2026 (approved) / 1 Oct 2026 (effective)

Prakash M. Patil retires; Rashesh Gogri becomes Chairman; Adhish Patil becomes MD; Uday Patil ceases as WTD; Harshit Savla and Harit Shah re-appointed

Described by company as an orderly succession; no change to strategy

15 May 2026

Risk Management Committee re-constituted

Governance refresh

9 May 2025

Two independent directors re-appointed for second terms

Postal ballot / AGM approvals

Shareholding Trend

Holder categoryMar 2025Jun 2025Sep 2025Mar 2026Jun 2026

Promoter & promoter group (%)

55.4855.2254.7255.0354.43

Governance Detail

Data pointValueSource

Promoter pledge

2.50% (Jun 2026); 2.47% (Mar 2026)

Finology Ticker

Mutual funds

9.81% (Sep 2025)

Choice India

FIIs

2.68% (Sep 2025); ~1.5% (Aug 2026, per share.market)

Choice India; share.market

Retail

~32.7% (Sep 2025)

Choice India

Top 10 institutional holders with stakes

Not publicly disclosed in retrieved sources

—

Competitive Landscape

Competitors by Segment

SegmentCompetitorOverlapRelative positioning

Bulk APIs (anti-diabetic, analgesics)

IOL Chemicals & Pharmaceuticals

Metformin and other high-volume APIs; also specialty chemicals

Comparable scale; faster recent growth

Bulk APIs

Granules India

Metformin, paracetamol and high-volume APIs; vertically integrated into formulations

—

Bulk APIs / intermediates

Aarti Pharmalabs (group company)

APIs, xanthine derivatives, intermediates

Higher margin; sister company under common chairman

APIs

Solara Active Pharma Sciences

Generic APIs for regulated markets

Turnaround story; smaller

APIs (anti-infective, anti-diabetic)

Wanbury

Metformin

Smaller

APIs (fluoroquinolones, anti-infectives)

Large integrated Indian generics (e.g., Aurobindo, Lupin — captive API)

Ciprofloxacin and similar molecules

Captive consumers and occasional competitors

APIs (all categories)

Chinese bulk-drug manufacturers (Shandong/Zhejiang/Hubei clusters)

Metformin, metronidazole, fluoroquinolones, ketoconazole

Principal price-setters; drive realisation cycles

Methylamines (specialty chemicals)

Balaji Amines; Alkyl Amines Chemicals

Methylamines

Established merchant producers; Aarti's Sayakha output is primarily captive

Specialty chemicals (benzene chemistry)

Aarti Industries (group company) and other benzene-chain producers

NCB/sulphonation chemistry

Group overlap rather than direct competition

Formulations (exports)

Mid-sized Indian export formulators (e.g., Alembic, Unichem, Indoco — illustrative)

Generic dosage forms in regulated/tender markets

Aarti is sub-scale in formulations

Peer Comparison FY2026

Metric (FY2026, INR Cr)Aarti DrugsIOL Chemicals & PharmaAarti Pharmalabs

Revenue from operations

2,565.32,319.11,819.4

EBITDA

311.6290.4379.0

EBITDA margin (%)

12.112.520.8

PAT

194.9137.7166.7

Revenue growth FY2026 (%)

716—

Competitor Detail

Q1 FY2027 comparisonAarti DrugsIOL Chemicals & Pharma

Revenue (INR Cr)

702.8756.3

Revenue growth YoY (%)

1937

EBITDA margin (%)

13.814.6

Company Snapshot

$296.2M

Revenue

1984

Founded

Mumbai, India

Headquarters

SWOT Analysis

Strengths

  • Molecule leadership: Company claims global #1 in Nimesulide, Ketoconazole, Metronidazole Benzoate, Tinidazole and fluoroquinolones (AGM 2026 presentation).
  • Operational backward integration: Sayakha methylamines at ~1,000 t/month (Mar 2026) and 65% utilisation (Q1 FY2027); salicylic acid >300 t/month.
  • Regulatory credentials: USFDA VAI classification for Tarapur E-22 (Dec 2024), enabling US supply of five APIs; USFDA-approved oncology formulation.
  • Credit strength: ICRA AA- (Stable)/A1+ and CRISIL AA-/Stable/A1+ reaffirmed in 2026; gearing 0.39x (Sep 2025).
  • Diversification momentum: Formulations +33% and specialty chemicals +37% in FY2026; regulated-market share up to 73%.
  • Shareholder-return track record: Four tender buybacks since FY2018 (latest ₹59.85 crore in 2024) plus dividend doubled to ₹2 in FY2026.

Weaknesses

  • Stagnant top line: Revenue CAGR of ~0.8% FY2022–FY2026; FY2026 revenue (₹2,565 crore) still below FY2023 peak (₹2,716 crore).
  • API concentration: API = 77% of FY2026 revenue; API growth only 2% in FY2026 and flat in Q4.
  • Compressed returns: ROCE fell to 11.5% in FY2026; PAT remains ~30% below FY2021 peak (₹280 crore).
  • Thin liquidity buffer: Unencumbered cash of ₹9.57 crore (Sep 2025) vs ~₹570 crore debt.
  • EHS track record: Three pollution-board actions in two years (MPCB Jul 2024, MPCB Sep 2025, GPCB Jul 2026).
  • Earnings quality: FY2026 PAT growth helped by a low tax rate/one-off refund (PAT ₹194.9 crore vs PBT ₹210.9 crore).

Opportunities

  • Margin recovery: Q1 FY2027 EBITDA margin 13.8% already within FY2027 target of 13.5–14%.
  • China+1 sourcing: New regulated customer audits at Tarapur (Jul 2025) suggest qualification pipeline.
  • Specialty-chemicals scale-up: +150% YoY in Q1 FY2027; salicylates downstream line to add value.
  • Export formulations: Exports 74% of formulation revenue in Q1 FY2027; Chile tender access.
  • Brownfield expansion: ₹300–400 crore planned on existing sites (lower execution risk than greenfield).
  • Tax overhang removed: Supreme Court dismissal (Aug 2026) of ₹230.7 crore IGST + ₹20.7 crore penalty claim frees management attention and removes a contingent liability.

Threats

  • Chinese price aggression: Management cites continued pricing pressure in select API segments (FY2026).
  • Regulatory shutdown risk: GPCB closure of Sayakha (Jul 2026) — even though revoked in 13 days — shows a single inspection can threaten the backward-integration thesis.
  • Input-cost volatility: Crude and West Asia risks flagged in May 2026 guidance.
  • USFDA re-inspection risk: VAI status is "minimally acceptable"; a future OAI would impair the regulated-market pivot.
  • Leverage creep: Capex of ₹150–200 crore p.a. plus a ₹300–400 crore brownfield programme against ~₹220 crore annual accrual (CRISIL).
  • Key-person/bandwidth risk: Rashesh Gogri now chairs Aarti Drugs and Aarti Pharmalabs while serving as VC & MD of Aarti Industries.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
6 May 2025Bombay HC ad-interim order in IGST refund disputeFirst relief in ₹230.7 crore tax matter
9 May 2025Two independent directors begin second termsBoard continuity
May 2025FY2025 results: PAT ₹168.2 crore; revenue down 5.6%Trough year for revenue
28 May 2025Annual Secretarial Compliance Report filed, noting minor observations and a resolved MPCB closureCompliance housekeeping
18–21 Jul 2025Q1 FY2026 results (revenue ₹590.8 crore, +6%; PAT ₹54.0 crore incl. ~₹15 crore tax refund); Sayakha trial production beginsStart of recovery
30 Aug 2025FY2025 Annual Report, 40th AGM notice and BRSR filedDisclosure
4 Sep 2025Commercial production at SayakhaBackward integration milestone
8–10 Sep 2025HCl leak at T-150; MPCB-directed closure of PTSCL chlorosulfonation; company says no material impactEHS risk materialisation
24 Sep 202540th AGMGovernance
6 Oct 2025Bombay HC allows writ; CGST order set asideMajor tax overhang removed (pending appeal)
7–10 Nov 2025Q2 FY2026 results: revenue ₹652.9 crore (+9% YoY)Steady growth
28 Jan 2026CRISIL reaffirms AA-/Stable/A1+ on ₹1,768 croreCredit stability
3–4 Feb 2026Q3 FY2026: revenue ₹602.9 crore (+8%), EBITDA margin 9.3%, PAT ₹40.5 crore (+58%); ₹2 interim dividendMargin trough; dividend doubled
Feb 2026Salicylic acid plant >300 t/monthRamp-up milestone
2 Mar 2026Tripharma Chile SpA incorporatedLatAm expansion
7 Mar 2026₹10 crore investment in Pinnacle approvedFormulation growth funding
16 Mar 2026GST Department files SLP in Supreme CourtTax overhang revived
24 Mar 2026ICRA reaffirms AA- (Stable)/A1+ on ₹1,452.80 croreCredit stability
Mar 2026Sayakha reaches ~1,000 t/monthOperational milestone
8–9 Apr 2026Investor-service notices (unclaimed dividend campaign; physical share transfer window)Routine
15 May 2026FY2026 results: revenue ₹2,567.7 crore (+7%), EBITDA ₹311.6 crore, PAT ₹194.9 crore (+16%); auditors re-appointed; RMC reconstitutedReturn to growth
23 May 2026Earnings call: FY2027 EBITDA margin guidance 13.5–14%; ₹300–400 crore brownfield capexGuidance
27 May 2026Analyst meet hosted by 360 ONE CapitalIR
10 Jun 2026Virtual investor meet hosted by Choice Institutional EquitiesIR
20 Jun 2026GPCB inspection at Sayakha identifies Water Act/consent non-compliancesTrigger for closure order
18 Jul 2026GPCB closure direction for Sayakha amines plant (effective in 15 days)Material EHS/regulatory risk
31 Jul 2026Board: Q1 FY2027 results; leadership transition approved; GPCB revokes closure (received same day)Multiple catalysts
1 Aug 2026Q1 FY2027 release: revenue ₹703.6 crore (+19%), EBITDA ₹96.9 crore (+30%, 13.8% margin), PBT ₹69.2 crore (+35%), PAT ₹50.1 crore (−7%); GPCB revocation disclosed with ₹10.20 lakh interim EDCStrong operating quarter
3 Aug 2026Q1 FY2027 earnings callIR
10 Aug 2026Supreme Court dismisses GST SLP; matter disposed in company's favourRemoves ₹251 crore contingent liability
Aug–Sep 2026FY2026 Annual Report, BRSR and 41st AGM notice filedDisclosure
26 Sep 202641st AGM (virtual)Shareholder approvals including MD appointment
30 Sep / 1 Oct 2026Leadership transition becomes effectiveNew era under Gogri/Adhish Patil
PendingQ2 FY2027 results — date not confirmed as of research date; MarketScreener projects ~22 Oct 2026 (unconfirmed); statutory deadline 14 Nov 2026Next catalyst

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

3 charts
Revenue by Segment (FY2025–FY2026): Total revenue from operations rose from INR 23,867 Mn in FY2025 to INR 25,653 Mn in FY2026.
Aarti Drugs Limited — Revenue by Segment (FY2025–FY2026)
Series (INR Mn)FY2025FY2026
Total revenue from operations23,86725,653
API19,38419,794
Formulations2,4893,312
Specialty Chemicals1,3001,783
Intermediates & Others694764

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.